US Patent

US8247415 — Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2034-12-23 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds of Formula (I) and their use in treating or preventing diseases mediated by the activation of β3-adrenoceptors.

USPTO Abstract

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4219 — vibegron

Patent Metadata

Patent number
US8247415
Jurisdiction
US
Classification
Method of Use
Expires
2034-12-23
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.